CopyMark Law Group
4.9/5
Drawing for HCI

USPTO serial 97169341

HCI

Reviewed by CopyMark Law Group

Reg. 7040282Status 700Registered
Filing date
Status date
Registration date
May 2, 2023
Examiner
MCBRIDE, THEODORE M
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with HCI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

JOHN P. MURTAUGH

JOHN P. MURTAUGH PEARNE & GORDON LLP1801 EAST 9TH STREET, SUITE 1200CLEVELAND, OH 44114-3108UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
035Assistance, advisory services and consultancy with regard to business planning; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; Business consulting services; Business consulting services in the field of potential medical cures including cell and gene therapies; Business consultation in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, regulatory affairs including preclinical, clinical and commercial stage, pharmaceutical preclinical and clinical research, development, chemistry, manufacturing and controls, and quality assurance/quality control; Business consulting services, namely, providing assistance in development of business strategies and creative ideation; Business management consulting and advisory services; Business support services, namely, business consulting to freelancers, start-ups, existing businesses and non-profit organizations; Consultancy and advisory services in the field of business strategy; Consulting services in the field of medical product approval for commercial purposes; International business consulting services relating to USA and outside of USA product, clinical and commercial development of investigational or approved medical products; New business venture development and formation consulting services; Promoting the exchange of information and resources within the scientific research communities to achieve advances in the field of 21st century transformational science; Providing consulting services in the field of regulatory submission management to medical companies to assist them with applications for medical device approval; Providing independent review of clinical trials for business purposes; Promoting technical and scientific investigation, research and experimentation in the field of scientific discovery through support of educational institutions and scientific organizationsACTIVEJun 30, 2017
036Financial consulting services, namely, advising others regarding intellectual property investments; Investment consultation in the fields of product, technical, regulatory, preclinical, clinical, and commercial diligence for innovative potential or investigational medical productsACTIVEJun 30, 2017
042Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Medical and scientific research information in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, regulatory affairs including preclinical, clinical and commercial stage, pharmaceutical preclinical and clinical research, development, manufacturing/CMC and quality assurance/quality control; Providing information about medical and scientific research; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Scientific and technological services, namely, scientific research in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; Scientific research consulting in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; Scientific research and development; Technological planning and consulting services in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific consulting and research services relating to foods and dietary supplements; Scientific research consulting in the field of cosmeticsACTIVEJun 30, 2017
044Consulting services in the field of health; Consulting services to health care providers in the field of treating life-changing or life-threatening diseasesACTIVEAug 31, 2017

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 2, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
May 2, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 14, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 14, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 25, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 9, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 28, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 27, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 27, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 17, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 17, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 17, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 11, 2022ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Oct 4, 2022PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Sep 20, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 19, 2022DOCKASSIGNED TO EXAMINER—
Dec 16, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 16, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance